Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Tim received his A.B. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. Sarah Reed is the General Counsel at RA Capital Management. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. From 1990- 1997, he held investment, business development, R&D, and marketing positions at DuPont Ventures. Hearing the stories of how patients couldn't afford the . Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Rebecca conducts due diligence on biotechnology companies at RA Capital. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Timothy Noyes is an Advisor for RA Capital Management. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Kritis primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. He earned his PhD in Biomedical Science & Translational Medicine from Cedars-Sinai Medical Center and completed his Postdoctoral Fellowship in Molecular Pathology & Oncology at Harvard Medical School. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Jessica Sagers is Head of Engagement at RA Capital Management. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Mario is a Venture Partner and Head of Vaccines at RA Capital. In addition, he designs graphics for all internal and external materials. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Les primary responsibility is to coordinate various technology related initiatives across the company. Peter Kolchinsky, RA Capital's founder and managing partner. Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. Phi Thach is an Executive Assistant at RA Capital Management. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. She worked previously in desktop publishing and as a freelance designer. Robert Nicol is a Venture Partner at RA Ventures (RAVen), focusing on company creation. Prior to joining RAVen, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Michael is Executive Vice President at Capstan Therapeutics. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Vikram trained in clinical pathology at the Brigham and Womens Hospital where he was chief resident. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . Mike earned his MBA from the Darden Graduate School of Business Administration. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Peter Kolchinsky was born at a key point in their lives. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Michael Varnum is a Research Assistant at RA Capital Management. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. Peter Balogh is an Analyst on the Investment Team at RA Capital Management. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. His research investigated chromatin structure and transcription factor binding. In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVens Venture Partners and EIRs. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Milind attended the residential Executive Program at The Wharton School of Management. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Maryann received her Bachelor of Science in English from Northeastern University. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Joel brings 40 years of BioPharma drug discovery and development experience to that role. A funny, joyous romance on the streets of south London, plus Jude Law is a menacing Captain Hook in the new Neverland coming-of-age adventure Simon Wardell Fri 28 Apr 2023 04.00 EDT During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. He also holds a B.A. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Cameron has a BA in Neurobiology from Harvard University. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Neil was a founder or founding team member of six companies incubated within RA Ventures, including Lusaris Therapeutics, Eliem Therapeutics ($ELYM), Aerovate Therapeutics ($AVTE), Imbria Pharmaceuticals, and Athenen Therapeutics (acquired by Eliem). Peter Kolchinsky is a father, scientist, investor, teacher, and author. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. He also provided additional system administration and training for the desktop engineering team. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Peyman holds a dual B.S. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Matthew Feresten is a Business Systems Analyst at RA Capital Management. Cameron is a Senior Research Assistant at RA Capital Management. He oversees the firm's financial functions, including middle office operations, accounting, valuation, tax and financial reporting. She holds a BBA in Marketing from Loyola University Maryland. Michael is the Chief Financial Officer at RA Capital Management. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. Toms primary responsibility is to support all aspects of trade and treasury operations. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. April 28, 2023 9:39am. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. Michael conducts due diligence on biotechnology companies at RA Capital. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Kate previously served as Health Law Assistant at Mintz. Peter Kolchinsky (PhD '01) is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002.He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled The Entrepreneur's Guide to a Biotech Startup, and serves as an advisor to startup companies and non-profits. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. He also serves on the board of the American . Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. RA Capital and CEO of Arcuate Therapeutics. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. From 1997-2000, Scott served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board ofDirectors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. Brian has a B.S. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. In addition to The Great American Drug Deal, he is the author of The Entrepreneurs Guide to a Biotech Startup. Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. Shannon is a Receptionist and Facilities Administrator at RA Capital Management. (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Adam was also an advisor and investor in A Late Quartet, an entrepreneurial feature film centered on a cellist diagnosed with Parkinsons disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Le Ho is a Business Systems Analyst at RA Capital Management. MarketScreener: Created by Investors for Investors! Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. So it's not patents holding back production. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. Her primary responsibilities are to assist with all finance operations related to the Firm. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors.

Three Stages Of Ecocriticism, Kydex Triple Pistol Mag Pouch, Quickjack Adjustable Perimeter Support For Mobile Homes, New Banking Regulations 2022, Articles P